Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEKAMLO vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of aliskiren (direct renin inhibitor) and amlodipine (dihydropyridine calcium channel blocker). Aliskiren inhibits renin, reducing angiotensin I and II formation; amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Treatment of hypertension (FDA-approved) as replacement therapy in patients adequately controlled on individual components,Off-label: Not established
Hypertension
One tablet (40 mg telmisartan/5 mg amlodipine) orally once daily; maximum dose: 80 mg telmisartan/10 mg amlodipine per day.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Amlodipine terminal half-life: 30-50 hours (mean 35 hours), allowing once-daily dosing; steady-state achieved after 7-8 days. Valsartan terminal half-life: ~6 hours, but pharmacodynamic effect persists due to tight AT1 receptor binding.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Aliskiren: minimal metabolism via CYP3A4; amlodipine: extensively metabolized by CYP3A4
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
TEKAMLO (amlodipine/valsartan) excretion: amlodipine is extensively metabolized in the liver with 60% of metabolites excreted renally and 20-25% via feces; unchanged drug in urine <10%. Valsartan is primarily excreted unchanged in feces (70-80%) via biliary elimination, and 13% in urine as unchanged drug.
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Amlodipine: ~97.5% bound to plasma proteins (albumin). Valsartan: 94-97% bound to serum proteins (mainly albumin).
Approximately 70-80% bound to plasma proteins, primarily albumin.
Amlodipine Vd: ~21 L/kg, indicating extensive extravascular distribution. Valsartan Vd: ~5-10 L/kg, indicating moderate distribution into tissues.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Amlodipine: oral bioavailability 64-90% (mean ~64%). Valsartan: oral bioavailability ~23% (range 10-35%). Both are administered orally only.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
No adjustment for GFR ≥30 m L/min. Contraindicated if GFR <30 m L/min due to telmisartan component. Amlodipine not dialyzable.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh A: No adjustment. Child-Pugh B: Use lowest available strength, titrate slowly; avoid if severe impairment.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Safety and efficacy not established in patients <18 years.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Start at lowest available strength (40/5 mg); titrate slowly due to increased risk of hypotension and renal impairment.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None
None.
Risk of hypotension/syncope in volume-depleted patients,Avoid use in pregnancy (potential fetal harm),Monitor renal function and electrolytes, especially in patients with renal artery stenosis,Peripheral edema (more common in women, dose-dependent)
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Concomitant use with aliskiren in patients with diabetes or renal impairment (e GFR <60 m L/min) due to increased risk of renal impairment, hypotension, and hyperkalemia,Pregnancy,History of angioedema with aliskiren
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 metabolism of amlodipine, increasing risk of toxicity. Limit high-potassium foods (e.g., bananas, oranges, leafy greens, salt substitutes) due to aliskiren's potential to raise serum potassium. Maintain adequate hydration but avoid excessive sodium intake. No significant interaction with alcohol but advised to limit consumption.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
First trimester: Fetal toxicities (oligohydramnios, renal dysfunction, skull ossification delay) with angiotensin II receptor blocker (ARB) class. Second/third trimester: Oligohydramnios, fetal renal failure, hypotension, hyperkalemia, skull hypoplasia; risk is highest in second and third trimesters.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
No human data; amlodipine excreted in breast milk (M/P ratio ~1.0), telmisartan unknown. Avoid use while breastfeeding due to potential for neonatal hypotension and renal effects.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
No dose adjustment recommended due to lack of pharmacokinetic studies in pregnancy; however, drug is contraindicated in pregnancy, especially second and third trimesters, and alternative antihypertensives should be used.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
Tekamlo is a fixed-dose combination of aliskiren and amlodipine. Monitor renal function and electrolytes due to aliskiren's renin inhibition; avoid in severe renal impairment (e GFR <30 m L/min). Amlodipine may cause peripheral edema, especially at higher doses. Gradual titration reduces edema risk. Do not use aliskiren with ACE inhibitors or ARBs in patients with diabetes or renal impairment (e GFR <60 m L/min).
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take this medication exactly as prescribed, usually once daily.,Do not use with other blood pressure medications unless directed by your doctor.,Avoid grapefruit and grapefruit juice as they can increase amlodipine levels and side effects.,Report signs of edema (swelling in ankles/feet), dizziness, or fainting.,Do not take if you are pregnant or planning to become pregnant; stop immediately if pregnant.,Do not use salt substitutes containing potassium without consulting your doctor.,Stay hydrated, but avoid excessive intake of potassium-rich foods (bananas, oranges, spinach).,Do not stop abruptly without medical advice; monitor blood pressure regularly.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEKAMLO vs ALDOCLOR-150, answered by our medical review team.
TEKAMLO is a Antihypertensive combination that works by Combination of aliskiren (direct renin inhibitor) and amlodipine (dihydropyridine calcium channel blocker). Aliskiren inhibits renin, reducing angiotensin I and II formation; amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEKAMLO and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEKAMLO is: One tablet (40 mg telmisartan/5 mg amlodipine) orally once daily; maximum dose: 80 mg telmisartan/10 mg amlodipine per day.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEKAMLO and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEKAMLO is classified as Category C. First trimester: Fetal toxicities (oligohydramnios, renal dysfunction, skull ossification delay) with angiotensin II receptor blocker (ARB) class. Second/third trimester: Oligohydr. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.